Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Neostem (NBS) Stock Declines After Pricing Secondary Public Offering
http://www.thestreet.com/story/13167046/1/neostem-nbs-stock-declines-after-pricing-secondary-public-offering.html?puc=yahoo&cm_ven=YAHOO
Before any body jumps on me for posting this article I HAVE ALWAYS POSTED GOOD AND BAD!!! I let you make your decisions!
MidPoint | David Mazzo discusses melanoma skin cancer awareness month
I totally agree with what you are saying, DO NOT GET ME WRONG! I believe NBS will eventually be worth a lot more than it is today. I do not understand how the PPS can constantly go down! They have had good news after good news and have gotten nowhere. The next catalyst will be the name change and we will then figure that out, then we have Japan on our heels! ROFLMAO where will we be after that?? We bought CSC (NBS20)How much did we buy that for?? I think I may be wrong but wasn't it equivalent to $5 a share and have dropped $3 a share?? LOL PCT is worth more than $2 a share by its self! We had good results on NBS10 and we dropped?? It just does not make sense.
I bought 20K shares yesterday for a loss of 14k today! That was my dry powder. I have never put this company down before but I feel what they did was wrong! Why say ""...The grant substantiates our approach to identifying and securing non-dilutive funding"" when they new the grant its self was going to cause dilution??
I still believe in the company do not get me wrong! But I believe that they did all this in the wrong way!
Brando5 you do realize the analyst price was higher than that a year ago?? I am just curious how long you have been in this stock? I do believe in there science I have been posting and promoting NBS for years(on this board about 6 months).
You do realize that they did a reverse split to get listed, when they did that the shares where worth 50cents a share BEFORE we had NBS20! They did a 10-1 split in June of 2013 so shares went up to $5 a share if you had 1000 shares at 50cents you now owned 100 shares at $5 again BEFORE we had NBS20! Now after all there achievement's which there has been a lot! I have posted them continuously and now we have NBS20 the shares will probably open at $2 a share!!(right now as I post it is $2.12 premarket) Those who where invested back in 2013 at 50 cents a share now have a equivalent of 20 cents a share after all of there time invested! That includes the good news from NBS10 and the purchase of NBS20 and we have lost more than half our value!
I have been invested in Bios for a very long time, I have made a lot of money also. This companies science I believe in with out a doubt! BUT YES I AM PISSED!! It is hard to believe they did not announce this Dollar for Dollar a head of this! How do they expect to keep investors when they build them up then kick them in the ass?? You talk about the analyst target price it use to be around $28 a share a year ago, they have not come near that. Yes maybe 3-5 yrs down the road they might.
You said "" The underwriter bought for $2 a share doesn't mean you can get it for that price now!"" you will be able to sometime today! You also said "" They bought $25 million dollars worth! You won't get $2 a share buying $500 worth!"" I think you will be rethinking that statement by noon! You also said "" Keep in mind this company has target prices from $12-$24 a share."" They had even a higher target price before NBS20!
I am very troubled why this company continues to go down on really good news!
THIS SEEMS TO ME TO HAVE ONLY BENIFITTED PEOPLE SHORTING THE COMPANY! hOW ABOUT THE LONGS???
You do realize Phase 3 will end in 2018 don't you?
I agree andy e I am in for 2 years and my PPS is $5.07 and now they are offering 12 million shares at $2??? I just bought a bunch today and could have got them tomorrow for 70 cents cheaper a share! Then Dr Mazzo comes out with a misunderstanding?? NOWHERE DID IT EVER SAY DOLLAR FOR DOLLAR MATCH! This to me just seams illegal! I lost 14 thousand just on what I bought today! That does not include what I will lose on my other shares! I feel tricked because he forgot to mention this??? Also the fact that he said “The grant substantiates our approach to identifying and securing non-dilutive funding for our development programs and helps position NeoStem as a leader among immuno-oncology therapy developers.” - See more at: http://www.neostem.com/media/press-releases/news-item/major-grant-advances-pioneering-melanoma-therapy-at-neostem/#sthash.zcB95fKC.dpuf
Why did he say that if he knew it was dollar for dollar?? I think if you cant trust a company without having to get a magnifying glass out there is problems!!
$2 a share??? Why not have offered it at the going rate??? NeoStem Prices $25,000,000 Public Offering of Common Stock
New York, May 27, 2015 -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), announced today the pricing of an underwritten public offering of 12,500,000 shares of common stock at a public offering price of $2.00 per share. The gross proceeds to NeoStem from this offering are expected to be $25,000,000 before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. The Company has granted the underwriter a 45-day option to purchase up to an aggregate of 1,875,000 additional shares of its common stock to cover over-allotments, if any. The Company intends to use the net proceeds from this offering for working capital, including research and development of cell therapeutic product candidates, especially its lead immuno-oncology program, NBS20, expansion of business units, strategic transactions and other general corporate purposes. The offering is expected to close on or about June 2, 2015, subject to the satisfaction of customary closing conditions.
Aegis Capital Corp. is acting as sole book-running manager for the offering.
The offering is being made pursuant to a shelf registration statement that the Company previously filed with the Securities and Exchange Commission (SEC) and which became effective on October 3, 2012. A preliminary prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC. Electronic copies of the preliminary prospectus supplement and, when available, electronic copies of the final prospectus supplement and accompanying prospectus relating to this offering may be obtained from the SEC's website at http://www.sec.gov or from Aegis Capital Corp., 810 7th Avenue, 18th Floor, New York, NY 10019 or via telephone at 212-813-1010 or email: prospectus@aegiscap.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About NeoStem, Inc.
NeoStem is a biopharmaceutical company pursuing the preservation and enhancement of human health globally through the development of novel cell-based individualized medicine therapeutics that prevent, treat or cure disease. The Company is developing therapies based on three platform technologies (immuno-oncology, ischemic repair and immunomodulation) with a focus on its lead, Phase 3 clinical program for NBS20 in immuno-oncology.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the timing and success of the proposed public offering. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include, among others, the uncertainties related to market conditions, the completion of the public offering on the anticipated terms or at all, the final terms of the proposed offering, and the satisfaction of customary closing conditions related to the proposed public offering. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the factors described under the heading, "Item 1A. Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on March 2, 2015 and those described in the Company's other periodic filings with the SEC. The Company undertakes no obligation to update or revise any forward-looking statements.
They should have stated that to begin with! Now they are offering the stock at a great sale price! $2 a share
Most the long term people are not in this stock at $2 or $3 dollars! I know I am at a average after my buy this morning at but my PPS at $5.07 a share I was about $6.60 so I am not feeling good about this! Why did Dr mazzo make that statement knowing they where going to have a offering??
I can not believe they need it for NBS20 as they state!! I just bought a shit load today and it is down
Neostem, Inc. (NBS) After Hours Trading $2.35 or -.28 a share or -10.65%
I would not have bought today if I knew they needed money still
Why did they say >>Dr. David J. Mazzo, NeoStem’s Chief Executive Officer. “The grant substantiates our approach to identifying and securing non-dilutive funding for our development programs and helps position NeoStem as a leader among immuno-oncology therapy developers.” - See more at: http://www.neostem.com/media/press-releases/news-item/major-grant-advances-pioneering-melanoma-therapy-at-neostem/#sthash.mW5TgI9x.dpuf
Dr. David J. Mazzo, NeoStem’s Chief Executive Officer. “The grant substantiates our approach to identifying and securing non-dilutive funding for our development programs and helps position NeoStem as a leader among immuno-oncology therapy developers.” - See more at: http://www.neostem.com/media/press-releases/news-item/major-grant-advances-pioneering-melanoma-therapy-at-neostem/#sthash.mW5TgI9x.dpuf
I guess he did not actually mean this??? He told us this on may21st 2015!
New York, May 27, 2015 -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), announced today that it is commencing an underwritten public offering of its common stock. The Company intends to use the net proceeds from this offering for working capital, including research and development of cell therapeutic product candidates, especially its lead immuno-oncology program, NBS20, expansion of business units, strategic transactions and other general corporate purposes. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Why does it say they need it especially in NBS20??? That is where the grant is for???
I honestly can not believe they threw this brick at us now????? Why not before the grant??? I thought that grant covered them and financing was out of the way for a while!! I wonder if news leaked and that is why a good day went bad!! I am so mad just bought a lot more today after a long wait, I thought financing was not a issue??
SPEECHLESS>>>NeoStem Announces Proposed Public Offering of Common Stock
New York, May 27, 2015 -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), announced today that it is commencing an underwritten public offering of its common stock. The Company intends to use the net proceeds from this offering for working capital, including research and development of cell therapeutic product candidates, especially its lead immuno-oncology program, NBS20, expansion of business units, strategic transactions and other general corporate purposes. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Aegis Capital Corp. is acting as sole book-running manager for the offering. The offering is being made pursuant to a shelf registration statement that the Company previously filed with the Securities and Exchange Commission (the "SEC") and which became effective on October 3, 2012. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, from Aegis Capital Corp., 810 7th Avenue, 18th Floor, New York, NY 10019 or via telephone at 212-813-1010 or email: prospectus@aegiscap.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About NeoStem
NeoStem is a biopharmaceutical company pursuing the preservation and enhancement of human health globally through the development of novel cell-based individualized medicine therapeutics that prevent, treat or cure disease. The Company is developing therapies based on three platform technologies (immuno-oncology, ischemic repair and immunomodulation) with a focus on its lead, Phase 3 clinical program for NBS20 in immuno-oncology.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the timing and success of the proposed public offering. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include, among others, the uncertainties related to market conditions, the completion of the public offering on the anticipated terms or at all, the final terms of the proposed offering, and the satisfaction of customary closing conditions related to the proposed public offering. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the factors described under the heading, "Item 1A. Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on March 2, 2015 and those described in the Company's other periodic filings with the SEC. The Company undertakes no obligation to update or revise any forward-looking statements.
Betting On Cancer Treatment? Keep An Eye On This Company
Ritesh Anan , Benzinga Staff Writer Follow
May 26, 2015 3:02pm
Betting On Cancer Treatment? Keep An Eye On This Company
Related NBS
NeoStem's Lead Immuno-Oncology Product Candidate, NBS20, Receives ATMP Classification From the European Medicines Agency
NeoStem Announces Expanded Cell Therapy Manufacturing Relationship With Kite Pharma
NeoStem Inc NBS recently received a grant of $17.7 million to fund the company's effort in research of cell therapy products for cancer from California Institute of Regenerative Medicine. Following the announcement of the grant, shares of NeoStem rose by over 20 percent.
NeoStem CEO Dr. David Mazzo was on Fox Business News recently to talk about the company's new cancer drug.
NBS20
"Our product is called NBS20; it's too early for it to have a name, but it's in late-stage clinical development," Mazzo said.
"It works by actually identifying within a cancer those cancer stem cells that proliferate and teaching the immune system to actually kill those selectively. So, it's a way to prolong survival in a way that no other treatment does."
Related Link: New Drug Could Transform Pancreatic Cancer Treatment
A Simple Procedure
On how the therapy would be delivered, Mazzo said, "It's actually quite simple. This is what many people call a cancer vaccine.
"So, it's administered as a subcutaneous injection. It's a very simple procedure to administer the drug, a little injection under the skin once a week for three weeks and then once a month for five months and that's it."
The Grant
Mazzo was asked about the kind of results the company got for NBS20 that led it to being awarded the $17.7 million grant. He replied, "We actually generated really phenomenal results and two phase-II trials and the most recent of those two was a controlled, randomized study where the patients received our treatment had a 72 percent survival rate at two years in comparison to a control group, which only had a 31 percent. And even in that study, that control group was an active control.
"So, the historical norm for those patients would have been a 25 percent survival rate. So, really a remarkable prolongation of life," Mazzo said.
Image Credit: Public Domain
.
Read more: http://www.benzinga.com/general/health-care/15/05/5537123/betting-on-cancer-treatment-keep-an-eye-on-this-company#ixzz3bKHRoPNP
You are right but the shorts or the Market Makers keep this stock down! Who knows who is doing it but the PPS should be a lot higher than it is!!!
NeoStem Announces Dr. Merrick Ross of MD Anderson Cancer Center as Lead Principal Investigator for Pivotal Phase 3 Trial for Metastatic Melanoma
Dr. Merrick Ross to Lead NeoStem's Phase 3 Trial of Immuno-Oncology Product Candidate NBS20
New York, May 26, 2015 -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a biopharmaceutical company developing novel, cell-based individualized medicine therapies, today announced the appointment of Dr. Merrick Ross, Professor of Surgery and Chief of the Melanoma Section, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center (MD Anderson), as the lead principal investigator for NeoStem's Intus study. The Intus study is a Phase 3 clinical trial investigating the efficacy of the Company's patient-specific targeted cancer immunotherapy candidate NBS20 (USAN = eltrapuldencel-T) in patients with stage III recurrent or stage IV metastatic melanoma.
"I have dedicated my career to helping patients with cancer to live the longest, highest-quality lives they can in each individual case," said Dr. Ross. "I have seen melanoma treatments evolve over the past 30 years and am looking forward to serving as study chairman for this pivotal Phase 3 trial."
Dr. Ross is a surgical oncologist with specific expertise in melanoma who has worked and taught at MD Anderson since 1989. Dr. Ross has published extensively in medical literature, frequently lectures both domestically and abroad and has been in leadership roles for several completed melanoma clinical trials at the institutional, national, and international level. He has also been the recipient of various honors, including the Charles M. McBride Distinguished Professorship in Surgical Oncology. Dr. Ross received his medical degree from the University of Illinois School of Medicine in Chicago, completed a residency in General Surgery at the University of Illinois Affiliated Hospitals in Chicago, and was Chief Resident at the University of Illinois Department of Surgery. Additionally, Dr. Ross completed a research fellowship at Scripps Clinic and Research Institute in La Jolla, California, and a surgical oncology fellowship at The University of Texas MD Anderson Cancer Center.
"We are very fortunate to have Dr. Ross serve as the lead principal investigator for the Intus study," said Dr. Douglas Losordo, Chief Medical Officer of NeoStem. "His expertise as a surgical oncologist and experience in melanoma particularly make him an invaluable resource to the trial as we work to advance NBS20. We are delighted to welcome the leadership of this esteemed physician-scientist."
For more information on the Intus Study please visit www.theintusstudy.com or www.clinicaltrials.gov/ct2/show/NCT01875653.
About NeoStem
NeoStem, Inc. is among the first of a new breed of immunotherapy companies with proven expertise and unique experience in cell process optimization, development, and manufacturing. NeoStem is a cell therapy leader with late-stage clinical programs based on a proprietary platform technology for immuno-oncology, as well as additional platform technologies for ischemic repair and immunomodulation, and capabilities that support other cell therapy developers. This integrated approach supports the industry in bringing significant life-improving medical treatments to market. www.neostem.com.
Dr. Mazzo, Fox Business interview May 22, 2015 This is jut great the news is getting out! You can watch it here!>> http://video.foxbusiness.com/v/4252139194001/pioneering-cancer-treatment/?#sp=show-clips
You may be asking the wrong person LOL But my answer is that financing I really do not think is a problem right now or for the coming year. I have believed in the science of NBS is as solid as it gets! I have been in this stock a little over 2 years now. I believe the valuation should have been in the high $6 a share range before this news but it has been plagued by shorts for at least the last year. In my opinion the market makers for some reason walk the PPS on this stock down everyday, if you go to http://www.nasdaq.com/symbol/nbs/after-hours it is afterhours now but I watch them walk it down 50 to 100 shares at a time. I do not think they can hold it down now! People have to realize this is the biggest grant ever awarded to a private company. To put $17-$18 million into something means a lot of people really believe they will succeed. They also have PCT which brings in money. I have seen analyst say NBS should be from $6 all the way to $20 a share by years end. At the price it is now it in my mind should be around the $8 to $12 dollar range by years end. If NBS (there trails are looking good)can cure a stage IV metastatic melanoma we will be over $50 a share easily in a few years. The science for this can be used on other cancers in the future. I believe the stock will also go up because now we are a target for a buyout IMHO! The big pharms have been slowly buying out small Bio's. They usually wait to they have a positive phase 2 or 3 trails then jump in! Stem Cells are the future of medicine and we have come to a point where they now understand how to use them to cure patients and that is why this stock is so valuable! NBS has the science that is working!
We got the $17 million dollar grant!!
NeoStem, Inc. News
May 21, 2015
Turning Cancer Against Itself: Major Grant Advances Pioneering Melanoma Therapy at NeoStem
Company on leading edge of research with experimental therapy targeting specific cancer cells
New York, May 21, 2015 -- NeoStem, Inc. (NASDAQ: NBS) announced Thursday that it will receive one of the largest research grants of its kind to support its pioneering treatment for patients with stage III recurrent or stage IV metastatic melanoma, a potentially breakthrough approach that teaches the immune system which cells to attack and kill.
The $17.7 million grant from the California Institute for Regenerative Medicine (CIRM), a distinguished and independent scientific body, is a significant endorsement of the potential for NeoStem's novel approach for treating metastatic melanoma, the most deadly form of skin cancer. The sheer scope of the award has important implications as it is expected to fund a significant portion of the pivotal Phase 3 clinical trial investigating a personalized cancer treatment and currently enrolling patients at centers across the United States.
NeoStem's therapeutic candidate, NBS20, uses a patient's own cancer cells - in essence, turning the cancer against itself - in a way that is unique. Instead of attacking the bulk of cancer cells, NeoStem's therapy targets a patient's cancer-initiating cells, often called "cancer stem cells," which are those that proliferate cancer cells, spreading the disease and forming new tumors throughout the body.
Trial results to date support the expectation that this novel approach will improve overall survival. In a Phase 2 randomized, controlled trial of the therapy, results showed a 72 percent two-year survival rate, compared with 31 percent in the control group.
NeoStem's belief is that if the Phase 3 trial is successful, and the therapy is then approved by the FDA, it could be a breakthrough in the treatment of metastatic melanoma patients and available as early as 2018.
The product candidate has been granted both Fast Track and Orphan Drug designations from the FDA, and the protocol is the subject of a Special Protocol Assessment with FDA. Additionally, the European Medicines Agency has classified NBS20 as an Advanced Therapeutic Medicinal Product.
"We are grateful to CIRM and the cancer experts who reviewed and endorsed our application. We firmly believe that this therapy has the potential to help people survive cancer longer and this grant helps us advance towards bringing this treatment to market," said Dr. David J. Mazzo, NeoStem's Chief Executive Officer. "The grant substantiates our approach to identifying and securing non-dilutive funding for our development programs and helps position NeoStem as a leader among immuno-oncology therapy developers."
The grant comes during National Melanoma Skin Cancer Awareness Month and just ahead of the summer outdoor season when preventing skin cancer - the most common type of cancer in the United States - is a priority.
Norm Beegun, a patient in one of the Phase 2 trials for NBS20 who lives in Los Angeles, California, commented, "After several years of receiving other treatments with limited long-term success, I have been disease-free for the past 11 years since the NeoStem treatment - and I remain so today. The medical need for those with late-stage melanoma is profound, but so is the potential of this therapy. It deserves attention and support. That's why I am so glad that CIRM is funding the kind of research that can help so many people."
NeoStem's research has potentially widespread applications for people with cancers of various solid tumor types, including ovarian, lung, colon, liver, renal and brain cancers.
Other therapies may treat existing cancer, but they may not be as likely as NeoStem's approach might be to prevent a recurrence of tumors. NeoStem is one of a small group of companies with an immunotherapy product actually in Phase 3 development.
NeoStem is a biopharmaceutical company developing novel personalized immuno-oncology medical treatments. CIRM, whose mission it is to accelerate the availability of stem cell treatments for patients with unmet medical needs, funds promising research programs involving all types of stem cells and across a wide range of diseases.
The grant is the largest CIRM has made since its Dec 31, 2014 official launch of CIRM 2.0 and one of the largest the organization has ever made to an industry sponsor. Use of any of the CIRM grant funds is subject to dollar-for-dollar match funding by NeoStem.
"CIRM 2.0 is designed to accelerate the development of treatments for people with unmet medical needs, and this project clearly fits that description," says Dr. C. Randal Mills, President and CEO of CIRM. "With the Board's approval today we will now get this work up and running within the next 45 days. But that's just the start. We are not just providing financial support; we are also partnering with these groups to provide expertise, guidance and other kinds of support that these teams need to help them be successful. That's the promise of CIRM 2.0. Faster funding, better programs and a more comprehensive approach to supporting their progress."
Unlike many other immuno-oncology products, in order to work as hypothesized NBS20 does not depend on a low-level intrinsic immune response from the patient. The therapy is intended to induce an immune response by "teaching" the immune system what cells to attack and kill. Furthermore, because of its unique mechanism of action, the therapy will likely be complementary and potentially even synergistic with other available therapies. It is expected to be very well tolerated by patients because it uses their own immune system to create a specific therapy.
The Intus trial is supported by results from two Phase 2 trials conducted with dendritic cells loaded with antigens from autologous tumor stem cells, now known as NBS20. The more recent of the two trials was a randomized trial comparing subcutaneous injections of NBS20 versus injections of autologous irradiated (inactivated) tumor stem cells in patients with advanced melanoma. The two-year survival rate of 72 percent corroborated one of the findings of the previous Phase 2 trial, in which a 73 percent two-year survival rate was demonstrated along with a five-year survival rate of 50 percent.
The U.S. melanoma market is approximately $1 billion per year, which is predominantly spent to treat metastatic melanoma.
For more information on the Intus Study, which will be enrolling at approximately 50 sites across the U.S, Canada, Australia and New Zealand, please visit www.theintusstudy.com or www.clinicaltrials.gov/ct2/show/NCT01875653.
About Metastatic Melanoma
Melanoma, which originates in pigment-producing cells known as melanocytes, is the most lethal form of skin cancer. Melanoma is often caused by unrepaired DNA damage to skin cells from UV radiation. Patients who have progressed to stage IV melanoma have a cancer that has metastasized-or spread-to distant sites in the body such as the lymph nodes, lungs, liver or brain. As a result, advanced melanoma is exceedingly difficult to treat, with a 5-year survival rate of approximately 15%. There are 20,000 estimated new cases of metastatic melanoma, and an estimated 10,000 deaths from metastatic melanoma, each year in the United States.
Treatments for stage IV melanoma are typically directed at slowing the growth of the cancer and prolonging survival. Current treatment options include radiation, chemotherapy, surgical resection, immunotherapy, or a combination approach. Unfortunately, most current approaches provide only temporary relief, either halting the growth of tumors for an average of 6-10 months or eliminating all tumors in only 10-20% of patients. Administering certain anti-melanoma drugs at higher doses appears to be more effective, but often results in more severe side effects.
About CIRM
At CIRM, we never forget that we were created by the people of California to accelerate stem cell treatments to patients with unmet medical needs, and to act with a sense of urgency commensurate with that mission. To meet this challenge, our team of highly trained and experienced professionals actively partners with both academia and industry in a hands-on, entrepreneurial environment to fast track the development of today's most promising stem cell technologies. With $3 billion in funding and over 280 active stem cell programs in our portfolio, CIRM is the world's largest institution dedicated to helping people by bringing the future of medicine closer to reality. https://www.cirm.ca.gov/
About NeoStem, Inc.
NeoStem is a biopharmaceutical company pursuing the preservation and enhancement of human health globally through the development of novel cell-based individualized medicine therapeutics that prevent, treat or cure disease. The Company is developing therapies based on three platform technologies (immuno-oncology, ischemic repair and immunomodulation) with a focus on its lead, Phase 3 clinical program for NBS20 in immuno-oncology. The combination of a rich therapeutics pipeline and an externally recognized in-house center for cell therapy process development and manufacturing has created an organization with unique capabilities for accelerated and efficient product development. www.neostem.com
NEOSTEM MIGHT GET 18 MILLION ON THURSDAY
Tuesday, May 19, 2015
NeoStem Up For $18 Million Melanoma Award from California
California's stem cell agency is expected to make an $18 million bet this week on a treatment by NeoStem, Inc., for a skin cancer that kills 10,000 persons a year in the United States alone.
Up for approval on Thursday is the company's application for an award to assist in a late stage trial that could produce a commercial product before the agency is expected to run out of money in 2020.
NeoStem is based in New York city but has operations in Irvine and Mountain View in California. It acquired California Stem Cell, Inc., in Irvine in April of 2014 for $124 million. California Stem Cell was founded by Hans Kierstead of UC Irvine, who is now president of NeoStem Oncology.
The $3 billion agency did not disclose the name of the company in keeping with its longstanding practice of concealing the identity of applicants.
However, company documents and SEC filings indicated that NeoStem was the applicant. It would be the first award by the agency to Neostem, which is a publicly traded firm.
The summary of the agency's review posted on its Web site said the funds would go for completion of a stage three trial for a tumor stem cell-targeted immunotherapy for metastatic melanoma, which accounts for 20,000 new cases annually.
The review cited "compelling results" from the phase two stage of the trial. NeoStem has reported separately that its stage two trial had a 72 percent survival rate after two years compared to 31 percent for the control group.
NeoStem said in SEC filings that the treatment is for the most lethal form of skin cancer and has estimated market size of $1 billion.
Helping to develop a marketable product would be a big score for the agency, which has yet to fund a commerical therapy after 10 years and $1.9 billion.
Its money for new awards will run out in 2020 at its current spending rate. No additional funding sources for the agency have surfaced at this point. Being able to cite development of a commercial therapy would be likely to generate considerable enthusiasm for the agency's continued work.
Both reviewers and the CIRM staff recommended approval of the NeoStem application at the CIRM governing board meeting on Thursday.
The action came on a split vote among reviewers, 6-3-5, with six recommending funding and five against funding, according to a CIRM document.. Three reviewers said the application needed improvement.
The CIRM summary of the review said,
"Reviewers considered the lack of mechanistic data and inadequate plan to gain understanding of therapeutic mechanism of action to be a major weakness and expressed concern regarding the ability of the applicant to enrol the proposal pivotal Ph3 (phase three) study as projected."
CIRM said, however, the vote and staff recommendation to fund the research "reflects both the high risk and the clear potential to impact unmet medical need."
The CIRM governing board almost never overturns approval of an award by its reviewers and staff.
The award would be one of the two first approved in CIRM's 2.0 program to fast-track cash to researchers, speed development of therapies and improve the quality of grant applications. The second award -- $5 million -- is for work immediately leading up to a clinical trial for a therapy for retinitis pigmentosa. Shaomei Wang and Clive Svendsen at Cedars-Sinai in Los Angeles are the likely key figures in that research. Reviewers voted 15-0 to fund the work.
Sphere: Related Content
Posted by David Jensen at 2:29 PM ShareThis
Labels: cirm 2.0, clinical trials, mills, neostem
http://californiastemcellreport.blogspot.com/2015/05/neostem-up-for-18-million-melanoma.html
Neostem has a lot of events coming up starting with>>
World Stem Cells and Regenerative Medicine Congress
May 20, 2015 - 3:30 PM GMT
Business Design Centre, London
Presenter: Dr. Robert Preti, President of PCT, Chief Scientific Officer of NeoStem
Topic: Accelerating Time To Market:Development and manufacturing considerations for cell therapy product commercialization
12th International Symposium on Stem Cell Therapy & Cardiovascular Innovations
May 28, 2015 - 11:18 AM CET
Aula Magna. Pabellón Docente. Hospital Universitario Gregorio Marañón, Madrid, Spain
Presenter: Dr. Douglas Losordo, Chief Medical Officer
Topic: Cell based therapies to prevent and cure heart failure. More than an adventure?
2015 Marcum MicroCap Conference
May 28, 2015 - 9:30 AM ET
Grand Hyatt New York, NY
Presenter: Dr. David J. Mazzo, Chief Executive Officer
Topic: Company Presentation
2015 ASCO Annual Meeting
June 1, 2015 - 1:15 – 4:15 PM CT
Presenter: Dr. Robert O. Dillman, Vice President, Oncology Poster: Phase III multicenter trial of eltrapuldencel-T: Autologous dendritic cells loaded with irradiated autologous tumor cells (DC-TC) in granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with metastatic melanoma (Intus trial) - See more at: http://www.neostem.com/media/events/#sthash.Hzfpow5P.dpuf
A recent Losordo Publication.
A logical direction for future research may be to combine growth factor and cell-based therapy; intramuscular gene therapy could be administered in the ischemic tissue as pretreatment of the target tissue to augment homing of implanted stem cells.
http://onlinelibrary.wiley.com/doi/10.1002/9781118504499.ch57/summary
Here is some news! It makes me so mad NBS does not get these articles out there, you have to search! http://www.4-traders.com/NEOSTEM-INC-13840447/news/NeoStem--New-Cell-Therapy-Data-Have-Been-Reported-by-Researchers-at-NeoStem-Inc-Modulating-the-Va-20380355/
Immunotherapy For Metastatic Melanoma Uses Patient’s Own Tumor Cells http://melanomanewstoday.com/2015/05/11/cryoport-supports-neostems-intus-study-metastatic-melanoma-treatment/
NeoStem Receives $15.63 Consensus Target Price from Brokerages (NYSE:NBS) http://www.dakotafinancialnews.com/neostem-receives-15-63-consensus-target-price-from-brokerages-nysenbs/157401/
To get in now would be perfect! I do not believe the price will go lower and it is more than a steal at this price! Wishing you luck in what ever you decide.
Happy Mothers day to all the Women and men who take care of there children!
NeoStem to Present at Multiple May and June Conferences
NEW YORK, May 4, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq: NBS), a biopharmaceutical company developing novel cell-based individualized medicine therapies, announced today that the Company's management and experts will present at multiple conferences in May and early June.
Research Seminar Series, Li Ka Shing Knowledge Institute (LKSKI)
Date and Time: Thursday, May 7, 2015, 1:00 PM ET
Venue: St. Michael's Hospital, Toronto, Canada
Website: http://www.stmichaelshospital.com/knowledgeinstitute/education.php
Presenter: Dr. Douglas Losordo, Chief Medical Officer
Topic: Cell Therapy for Cardiovascular Disease
World Stem Cells and Regenerative Medicine Congress
Date and Time: Wednesday, May 20, 2015, 3:30 PM GMT
Venue: Business Design Centre, London
Website: http://www.terrapinn.com/conference/stem-cells/
Presenter: Dr. Robert Preti, President of PCT, Chief Scientific Officer of NeoStem
Topic: Accelerating Time To Market: Development and manufacturing considerations for cell therapy product commercialization
2015 Marcum MicroCap Conference
Date and Time: Thursday, May 28, 2015, 9:30 AM ET
Venue: Grand Hyatt New York, NY
Website: http://www.marcumllp.com/MicroCap
Presenter: Dr. David J. Mazzo, Chief Executive Officer
Topic: Company Presentation
Webcast: www.neostem.com/investors/investor-events/
12th International Symposium on Stem Cell Therapy & Cardiovascular Innovations
Date and Time: Thursday, May 28, 2015, 11:18 AM CET
Venue: Aula Magna. Pabellón Docente. Hospital Universitario Gregorio Marañón, Madrid, Spain
Website: http://www.cardiovascularcelltherapy.com/
Presenter: Dr. Douglas Losordo, Chief Medical Officer
Topic: Cell based therapies to prevent and cure heart failure. More than an adventure?
International Society for Cell Therapy 2015 Annual Meeting
Date and Time: Friday, May 29, 2015, 12:45 PM PT
Venue: Caesars Palace, Las Vegas, Nevada
Website: http://www.celltherapysociety.org/
Workshop Participant: Dr. Jacob Ceccarelli, Biotechnology Engineer, PCT
Topic: Corporate Tutorial – Fresenius Kabi
2015 ASCO Annual Meeting
Date and Time: Monday, June 1, 2015, 1:15 – 4:15 PM CT
Venue: McCormick Place, Chicago, Illinois
Website: http://am.asco.org/
Presenter: Dr. Robert O. Dillman, Vice President, Oncology
Poster: Phase III multicenter trial of eltrapuldencel-T: Autologous dendritic cells loaded with irradiated autologous tumor cells (DC-TC) in granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with metastatic melanoma (Intus trial)
http://www.streetinsider.com/Press+Releases/NeoStem+to+Present+at+Multiple+May+and+June+Conferences/10515324.html
New Investors Presentation at Neostem updated May! It is the slide presentation at the bottom of the page. http://www.neostem.com/investors/overview/
I still can not find Vsel TM. anywhere on there site or in the new presentation. Does anybody know what is happening to that??
NeoStem Inc 387.8% Potential Upside Indicated by The Benchmark Company
NeoStem Inc using SYMBOL code NASDAQ:NBS has had its stock rating noted as ‘Reiterated’ with the recommendation being set at ‘BUY’ this morning by analysts at The Benchmark Company. NeoStem Inc are listed in the Health Care sector within NASDAQ. The Benchmark Company have set a target price of 12 USD on its stock. This is indicating the analyst believes there is a potential upside of 387.8% from the opening price of 2.46 USD. NeoStem Inc NASDAQ:NBS has a 50 day moving average of 3.33 USD and a 200 Day Moving Average share price is recorded at 4.45 USD. The 52 week high for the share price is currently at 7.23 USD while the 52 week low for the share price is 2.34 USD.
NeoStem Inc NASDAQ:NBS is a provider of cellular therapy products. The Company is engaged in the development of cell therapy products; it also provides development and manufacturing services. NeoStem’s research and clinical development activities are aimed at three therapeutic platforms: ischemic repair (CD34 Cell Program), immune modulation (T Regulatory Cell Program) and tissue regeneration (VSELTM Technology). The Company develops therapies to address ischemia through its CD34 Cell Program. The Company focuses on the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs, restoring their normal function. The Company’s AMR-001 is the product candidate in its CD34 Cell Program and is being developed to treat damaged heart muscle following an acute myocardial infarction (heart attack) (AMI
http://www.directorstalkinterviews.com/neostem-inc-387-8-potential-upside-indicated-by-the-benchmark-company/412662602
Oh I forgot to add, most people think the stock buy with Aspire pertains to the previous one in 2014, No it does not. I feel they slipped this in without having a separate sec form hoping it would go unnoticed!
Those other means include the continued use of a common stock purchase agreement with Aspire. In 2014, we entered into a $30 million Purchase Agreement, of which we had $11.7 million remaining available (subject to an issuance limit of 1.4 million shares) at March 31, 2015. In addition, on May 4, 2015, we entered into a new Common Stock Purchase Agreement with Aspire, whereby Aspire is committed to purchase up to an aggregate of $30 million of shares of NeoStem common stock over a P24M-month term
I had to leave yesterday because I was so upset, I was actually left speechless and did not wont to post something I would regret! My thoughts on the situation is that Neostem has still not got the idea of ""Putting the horse in front of the cart"" and again we suffer! I do not know what there plans is but I do know they are loosening to much by the way they do it. Here are my reasons for this thought
1. Why not announce ahead of time the company is transforming, get people excited and let them in on the plans?? Let them know what has to go and where the future is taking us. They actually could have got people to hold the stock and PPS, maybe even new investors looking for that upside. Instead they blind sided everyone not knowing what was going on. People do not like to not know what is happening when it involves there money. I think I can make the statement that everybody already knew that we where not going to have great 1st quarter. That is not what made the stock drop.
2. Name change? Probably a good reason but why not have mentioned the reason for this? There are a lot of reasons people change the name of there company, some are good and some are bad! We don't know if we are incorporated, partnered, bought, bankrupt or just looking to move on with a new name? I think a lot of people wondered about this.
3. What happened to the Tissue Regeneration Program VSELsTM? Its page is gone off the site? Did we not get a grant to continue this program? Is this temporary or has the trade mark been sold? Who knows I am in the dark!
4. Management. Yes we have new management but I do not think there approach is any different than the last. They need somebody in there that has a good public approach on how to advertise this stock. I did say advertise because your display of the company can make it or break it!
My opinion>>
Why not announced a couple weeks of head of time we are>>>
TRANSFORMING this company which includes a corporate name and brand identity in the coming weeks to emphasize the Company’s therapeutic development focus on immune therapy and its integrated approach to cell therapy. We have big and positive changes we will be announcing along the way! You will see changes to our site, please give them time to be all updated, we will announce when that is done!
People would not have been blind sided. They could have got us excited by some CEO post about what this would included and that our future is going to be positive! Actually no matter what they put out now we have lost a lot of PPS and especially confidence in the company, I feel this could have been avoided. These things are hard to recover from. Not to bring up old crap but just like the first results of NBS10 they waited to long to reply, we all took that hit! The second time you think they would have been ready? Again the PPS dropped no reply for a couple days?? We have not recovered yet! Then yesterday did not help at all, down we go again!
I feel and I know it is true that we have had good results!! Then why is the PPS so low? We have dropped to almost nothing and yes it is a good buying opportunity with out a doubt! You need confidence in a company to buy and hold the PPS.
Last let me say, I believe in NBS, there science, there trails. THEY ARE THE FUTURE OF MEDICNE ! I just wish they would adopt that thought when printing articles or displaying news! I wish they would keep the ball rolling with updates about our products, our future! Little words mean a lot! I wish the CEO would take 10 minutes a week to post on his blog( it does not have to be a lot, little progress reports, anything)
I am left a little speechless here! There where things that where said that surprised me
1.NeoStem has completed our transformation into a Phase 3 immuno-oncology company??
What?? Why was not anybody informed about this? If you go to there web site NeoStem's VSEL™ Technology for Retinal Repair this is totally gone and some other stuff!!
2.Entered into a new Common Stock Purchase Agreement with Aspire Capital Fund, LLC (Aspire), whereby Aspire is committed to purchase up to an aggregate of $30 million of shares of NeoStem stock over a 24-month term, supplementing NeoStem's cash, cash equivalents and marketable securities of $19.1 million as of end of the first quarter;
What?? When did this happen???? I honestly do not remember a sec filing on this?? Is this not dilution??
I am a little baffled over the new name also, what ever it might be?? I think this is why the stock went down today! They always put the cart in front of the horse! I wonder if we are going into a partnership or something got sold??
Name change?? Did anybody notice this in there 2015 first quarter read out?
• Change of corporate name and brand identity in the coming weeks to emphasize the Company's therapeutic development focus on immune therapy and its integrated approach to cell therapy;
NeoStem, Inc. Announces 2015 First Quarter Financial Results and Provides Corporate Update
By GlobeNewswire, May 05, 2015, 07:30:00 AM EDT
Vote up
loading
A A A
NEW YORK, May 5, 2015 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a biopharmaceutical company developing novel, cell-based individualized medicine therapies, announced today 2015 first quarter results and provided an update on its business.
"NeoStem has completed our transformation into a Phase 3 immuno-oncology company with the recent randomization of the first patient in the pivotal Phase 3 Intus trial for NBS20. This is a trial that has been granted a Special Protocol Assessment (SPA) by the FDA. In addition, the NBS20 program has been granted Orphan Drug and Fast Track designations by FDA, all based on compelling published Phase 2 results. We look forward to advancing this therapy towards addressing the significant unmet need of metastatic melanoma treatment," said Dr. David J. Mazzo, Chief Executive Officer of NeoStem.
Operational Highlights
In the year to date, NeoStem's operational highlights included:
• Strengthened leadership with appointments of David J. Mazzo, PhD as Chief Executive Officer, Robert S. Vaters as President and Chief Financial Officer, and Peter G. Traber, MD to the Board of Directors;
• Randomized the first patient in the Phase 3 Intus Study for stage III recurrent and stage IV metastatic melanoma, an event which defers the first principal payment for the Company's debt facility until April 2016;
• Entered into a new Common Stock Purchase Agreement with Aspire Capital Fund, LLC (Aspire), whereby Aspire is committed to purchase up to an aggregate of $30 million of shares of NeoStem stock over a 24-month term, supplementing NeoStem's cash, cash equivalents and marketable securities of $19.1 million as of end of the first quarter;
• Received Advanced Therapeutic Medicinal Product classification for the Company's most advanced product candidate, NBS20, from the European Medicines Agency;
• Expanded office space at Irvine, CA facility to support the clinical trial operations and manufacturing of NBS20 for the Intus Study, and also added office space in Basking Ridge, NJ to accommodate continued growth;
• Received grant subaward from University of California, Irvine (CIRM), providing non-dilutive financing for discovery research;
• Completed expansion in Allendale, NJ facility, adding laboratory, clean room suites and support facilities, and in Mountain View, CA facility, adding manufacturing capacity with additional clean rooms, laboratory space and support facilities;
• Announced an expanded cell therapy manufacturing relationship with Kite Pharma that will serve as a model for future collaborations with clients;
• Announced an agreement with Invetech Pty Ltd. to develop a closed-processing system for cell therapy manufacturing, to provide a flexible small-scale process suitable for GMP manufacturing of autologous and other patient-specific products;
• Announced one-year follow-up results from the Company's Phase 2 PreSERVE study for patients with left ventricular dysfunction post-ST elevation myocardial infarction (STEMI) supporting previous observation of dose-dependent signals across multiple endpoints.
2015 First Quarter Financial Highlights
Total revenue for the quarter was approximately $3.2 million compared to $4.1 million for Q1 2014, a decrease of 22%, which was primarily due to lower reported Clinical Services revenues. The decline, however, was impacted by the net incremental deferral of $1.2 million of additional revenue during the three months ended March 31, 2015, based on our revenue recognition policy. Accordingly, total non-GAAP Adjusted Revenue, which excludes the impact of deferred revenue adjustments, was approximately $4.3 million for both Q1 2015 and Q1 2014, respectively (see below for reconciliation), reflecting adjustments for numerous process development contracts still in process that were not recognized under the Company's revenue recognition policy.
Research and development expenses were approximately $6.8 million for the quarter compared to $4.8 million for Q1 2014. The increase was primarily related to an increase in expenses for the Company's immuno-oncology program, including the initiation of activities to support the commencement of the Intus Phase 3 clinical trial for NBS20, as well as a minor increase in expenses for the immune modulation program efforts to develop T Regulatory cells (Tregs). In addition, there was a minor overall increase in expenses for the ischemic repair program, whereby lower expenses associated with the PreSERVE AMI Phase 2 clinical trial for the Company's product candidate NBS10 were offset by higher expenses associated with activities to support a potential critical limb ischemia development program in Japan.
Selling, general and administrative expenses were approximately $11.1 million for the quarter compared to $9.0 million for Q1 2014, and included $3.2 million and $3.3 million, respectively, of equity-based compensation. The increase was primarily related to expenses associated with executive management changes in the first quarter of 2015, including one-time new hire compensation-related costs as well as separation-related costs. In addition, the increase reflects additional operating activities in connection with the acquisition in May 2014 of California Stem Cell, Inc. These increases were partially offset by lower strategic and corporate development activities in the first quarter of 2015 compared to Q1 2014.
Net loss for Q1 2015 was approximately $19.2 million compared to net loss of $13.8 million for Q1 2014. Net loss for Q1 2015 excluding non-cash charges was $14.3 million, compared with $9.3 million for Q1 2014 (see below for reconciliation).
At March 31, 2015, NeoStem's cash, cash equivalents and marketable securities totaled $19.1 million.
2015 Outlook
In 2015, NeoStem's management expects significant additional achievements, principal among them are the following:
• Continued enrollment in the Intus Phase 3 trial for NBS20;
• Change of corporate name and brand identity in the coming weeks to emphasize the Company's therapeutic development focus on immune therapy and its integrated approach to cell therapy;
• Filing an IND in Japan for one or more programs under Japan's new regenerative medicine law which enables an expedited path to conditional approval for regenerative medicine products based on the demonstration of sufficient safety evidence and signals of efficacy;
• Finalization of decision on next development steps for NBS10 based on available PreSERVE results;
• Receipt of additional non-dilutive (i.e., grant) funding to support development programs;
• Continued growth in the Company's client services (PCT) business.
Use of Non-GAAP Financial Measures
The Company uses "Adjusted Revenues" and "Net Loss Excluding Non-Cash Charges" as non-GAAP financial measures in evaluating its performance.
• Adjusted Revenues represents GAAP revenues less the impact of the change in unearned revenues. The Company believes that providing this measure to investors provides important supplemental information relating to its performance and permits investors and management to evaluate the impact of the Company's revenue-generating activities on its cash position. Additionally, the Company believes this information is frequently used by securities analysts, investors and other interested parties in the evaluation of performance. Management uses, and believes that investors benefit from, this non-GAAP financial measure in assessing the Company's revenue-generating activities, as well as in planning, forecasting and analyzing future periods.
• Net Loss Excluding Non-Cash Charges represents net loss, less equity-based compensation, depreciation and amortization, and other non-cash adjustments included in calculating net loss. The Company believes that providing this measure to investors provides important supplemental information relating to its performance and permits investors and management to evaluate the core operating performance and cash utilization of the Company by excluding the use of these non-cash adjustments. Additionally, the Company believes this information is frequently used by securities analysts, investors and other interested parties in the evaluation of performance. Management uses, and believes that investors benefit from, this non-GAAP financial measure in assessing the Company's operating results, as well as in planning, forecasting and analyzing future periods.
These non-GAAP measures have limitations as an analytical tool, and investors should not consider these measures in isolation, or as a substitute for analysis of the Company's results as reported under generally accepted accounting principles in the United States ("GAAP"). For example, Net Loss Excluding Non-Cash Charges does not reflect the Company's cash expenditures, future requirements for capital expenditures, contractual commitments or cash requirements for working capital needs. Although depreciation and amortization are non-cash charges, the assets being depreciated or amortized often will have to be replaced in the future, and Net Loss Excluding Non-Cash Charges does not reflect any cash requirements for such replacements. Given these limitations, the Company relies primarily on its GAAP results and uses the Net Loss Excluding Non-Cash Charges measure only as a supplemental measure of its financial performance and cash utilization.
GAAP to Non-GAAP Reconciliation
Adjusted Revenues Reconciliation (unaudited)
(in millions) For the three
months ended
March 31, 2015 For the three
months ended
March 31, 2014
Revenues $3.17 $4.06
Change in Unearned Revenue 1.17 0.21
Adjusted Revenues $4.34 $4.27
Net Loss Excluding Non-Cash Charges Reconciliation (unaudited)
(in millions) For the three
months ended
March 31, 2015 For the three
months ended
March 31, 2014
Net loss $ (19.2) $ (13.8)
Equity-based compensation 3.7 3.9
Depreciation and amortization 0.6 0.4
Changes in acquisition-related contingent consideration 0.6 0.2
Other 0.0 0.0
Net Loss Excluding Non-Cash Charges $ (14.3) $ (9.3)
About NeoStem, Inc.
NeoStem is a biopharmaceutical company pursuing the preservation and enhancement of human health globally through the development of novel cell based individualized medicine therapeutics that prevent, treat or cure disease. The Company is developing therapies based on three platform technologies (immuno-oncology, ischemic repair and immunomodulation) with a focus on its lead, Phase 3 clinical program for NBS20 in immuno-oncology. The combination of a rich therapeutics pipeline and an externally recognized in-house center for cell therapy process development and manufacturing has created an organization with unique capabilities for accelerated and efficient product development. www.neostem.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, the Company's ability to develop and grow its business, the successful development of cellular therapies with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's Immuno-Oncology Program, Ischemic Repair Program, Immune Modulation Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry, and the performance and planned expansion of the Company's wholly-owned subsidiary and its center of excellence for cell therapy process development, engineering and manufacturing, PCT, as well as its efforts to expand its capabilities into the cell therapy tools market. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 2, 2015, and in the Company's other periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside of its control.
CONTACT: NeoStem, Inc.Eric Powers
Manager of Communications and Marketing
Phone: +1-212-584-4173
Email: epowers@neostem.com
Source: NeoStem Inc.
Read more: http://www.nasdaq.com/press-release/neostem-inc-announces-2015-first-quarter-financial-results-and-provides-corporate-update-20150505-00368#ixzz3ZGQLyktg
I wish I did lol, been trying to find out! I do not think they are trade on the stock exchange but I google it every so often to see if I can find out! A nother one is the invisible cloak DO NOT LAUGH they have invented it! Can you imagine what that stock would go up to?? Hide a plane? LOL here is the story on that and also google it, it is amazing! http://www.cnn.com/videos/tech/2015/01/07/orig-researchers-invent-a-cloaking-device-npr.cnn
I post at a lot of boards keeps me busy! NBS is like a baby to me only thing it has a growth problem LOL! Soon as they partner things will get a lot better really fast! The problem of a lot of this is also the BIG PHARMS they are slowly coming around and slowly getting involved because I think they are really starting to realize they can not hold stem cells down! You will see articles out about how stem cells failed, if you look a lot of them are actually sponsored by different drug companies. They want to bring to everybody's attention when one fails even if they have to pay for it. They know that stem cells will cut into there profits down the line! You know they have a vaccine out in trails for Heroin addiction it stops the use of heroin immediately but no one will sponcer them! If the get everybody off heroin they will not need all the drugs to treat them or have all the people addicted to opiate pain relievers. They have done trails on rats but can not get funding any further. Here is the story on that! If they ever get funded buy stock as soon as possible in that company it will go to the moon with all the addicts we have in the world! http://time.com/3654784/why-youve-never-heard-of-the-vaccine-for-heroin-addiction/
You got in at a very good price! mine is a lot higher but I believe in the end I will be way ahead!